Skip to main content
. 2024 May 23;39:239–254. doi: 10.1016/j.bioactmat.2024.05.014

Fig. 4.

Fig. 4

Fa-PCD/pCKb11/iPD-L1 treatment promotes proliferation and activation of lymphocytes. ID8 cells were treated with different nanocomposites for 48 h. Then the cell supernatants were collected for treating lymphocytes. (A) Cell viability of lymphocytes assessed by CCK8. (B) Activated T lymphocytes detected by FCM, which were defined as CD8+CD69+, CD8+IFN-γ+, CD4+CD69+, CD4+IFN-γ+ lymphocytes. (n = 3, *p < 0.05, **p < 0.01, ****p < 0.0001, n. s. , no significance; One-way ANOVA).